此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

AZD5305 作为单药治疗和联合抗癌药物治疗晚期实体恶性肿瘤的研究 (PETRA)

2026年9月18日 更新者:AstraZeneca

一项模块化 I/IIa 期、开放标签、多中心研究,以评估递增剂量的 AZD5305 作为单一疗法和与抗癌药物联合治疗晚期实体恶性肿瘤患者的安全性、耐受性、药代动力学、药效学和初步疗效

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

研究概览

详细说明

This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.

研究类型

介入性

注册 (实际的)

702

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100142
        • Research Site
      • Changchun、中国、130021
        • Research Site
      • Changsha、中国、410013
        • Research Site
      • Chengdu、中国、610041
        • Research Site
      • Chongqing、中国、400030
        • Research Site
      • Guangzhou、中国、510060
        • Research Site
      • Harbin、中国、150081
        • Research Site
      • Jining、中国、272029
        • Research Site
      • Shandong、中国
        • Research Site
      • Shanghai、中国、200032
        • Research Site
      • Shanghai、中国、200025
        • Research Site
      • Taiyuan、中国、030001
        • Research Site
      • Wuhan、中国、430079
        • Research Site
      • Xi'an、中国、710061
        • Research Site
      • Chernivtsі、乌克兰、58013
        • Research Site
      • Ivano-Frankivsk、乌克兰、76018
        • Research Site
      • Kyiv、乌克兰、03022
        • Research Site
      • Uzhhorod、乌克兰、88000
        • Research Site
      • Moscow、俄罗斯、115478
        • Research Site
      • Moscow、俄罗斯、117997
        • Research Site
      • Moscow、俄罗斯、111123
        • Research Site
      • Moscow、俄罗斯、143442
        • Research Site
    • British Columbia
      • Vancouver、British Columbia、加拿大、V5Z 1K1
        • Research Site
    • Ontario
      • Toronto、Ontario、加拿大、M5G 2M9
        • Research Site
    • Quebec
      • Montreal、Quebec、加拿大、H3T 1E2
        • Research Site
      • Montreal、Quebec、加拿大、H2X 0A9
        • Research Site
      • Budapest、匈牙利、1122
        • Research Site
      • Budapest、匈牙利、1062
        • Research Site
      • Budapest、匈牙利、1082
        • Research Site
      • Milan、意大利、20141
        • Research Site
      • Milan、意大利、20132
        • Research Site
      • Modena、意大利、41125
        • Research Site
      • Naples、意大利、80131
        • Research Site
      • Padova、意大利、35128
        • Research Site
      • Roma、意大利、00168
        • Research Site
      • Brno、捷克语、656 53
        • Research Site
      • Prague、捷克语、15006
        • Research Site
      • Chūōku、日本、104-0045
        • Research Site
      • Kōtoku、日本、135-8550
        • Research Site
      • Bydgoszcz、波兰、85-796
        • Research Site
      • Gdansk、波兰、80-214
        • Research Site
      • Gdynia、波兰、81-519
        • Research Site
      • Grzepnica、波兰、72-003
        • Research Site
      • Lodz、波兰、90-302
        • Research Site
      • Torun、波兰、87-100
        • Research Site
      • Warsaw、波兰、02-781
        • Research Site
      • Heidelberg、澳大利亚、3084
        • Research Site
      • Melbourne、澳大利亚、3000
        • Research Site
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Research Site
      • Boston、Massachusetts、美国、02215
        • Research Site
    • New York
      • New York、New York、美国、10021
        • Research Site
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • Research Site
    • Texas
      • Houston、Texas、美国、77030
        • Research Site
      • Cambridge、英国、CB2 0QQ
        • Research Site
      • Manchester、英国、M20 4BX
        • Research Site
      • Oxford、英国、OX3 7LE
        • Research Site
      • Sutton、英国、SM2 5PT
        • Research Site
      • Barcelona、西班牙、08035
        • Research Site
      • Madrid、西班牙、28041
        • Research Site
      • Madrid、西班牙、28040
        • Research Site
      • Madrid、西班牙、28050
        • Research Site
      • Málaga、西班牙、29010
        • Research Site
      • Pozuelo de Alarcón、西班牙、28223
        • Research Site
      • Seville、西班牙、41013
        • Research Site
      • Seoul、韩国、03080
        • Research Site
      • Seoul、韩国、03722
        • Research Site
      • Seoul、韩国、05505
        • Research Site
      • Seoul、韩国、06351
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 130年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Age ≥ 18 at the time of screening
  • Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..
  • Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)
  • Life expectancy ≥ 12 weeks
  • Progressive cancer at the time of study entry
  • Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B
  • Adequate organ and marrow function as defined by the protocol.
  • For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.

For Part A:

- Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)

For Part B:

- Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).

Key Exclusion Criteria:

  • Treatment with any of the following:

    1. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
    2. Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment
    3. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
    4. Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
  • Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong inhibitors or inducers.

  • Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.

  • Receiving continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for any reason.

  • Major surgery within 4 weeks of the first dose of study treatment.

  • Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.

  • Any history of persisting (> 2 weeks) severe pancytopenia due to any cause

  • Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.

  • patient with known predisposition to bleeding (e.g., active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).

  • Cardiac conditions as defined by the clinical study protocol

  • Other cardiovascular diseases as defined by any of the following:

    1. Symptomatic heart failure,
    2. uncontrolled hypertension,
    3. hypertensive heart disease with significant left ventricular hypertrophy
    4. acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
    5. cardiomyopathy of any etiology
    6. presence of clinically significant valvular heart disease
    7. history of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (< 100 beats per minute) are permitted.
    8. subjects with atrial fibrillation and optimally controlled ventricular rate are permitted
    9. transient ischaemic attack, or stroke within 6 months prior to screening
    10. patients with symptomatic hypotension at screening
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).

  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305

  • Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).

Prior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.

other module-specific criteria may apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Module 1: AZD5305 Monotherapy

AZD5305 Monotherapy

Oral PARP inhibitor

实验性的:Module 2: AZD5305 + Paclitaxel

AZD5305 + Paclitaxel

Oral PARP inhibitor

IV Anti-microtubule agent

实验性的:Module 3: AZD5305 + Carboplatin with or without Paclitaxel

AZD5305 + Carboplatin with or without Paclitaxel

Oral PARP inhibitor

IV Anti-microtubule agent

IV Platinum chemotherapeutic

实验性的:Module 4: AZD5305 + Trastuzumab Deruxtecan

AZD5305 + T- DXd

Oral PARP inhibitor

IV Antibody-drug conjugate

实验性的:Module 5 AZD5305 + Datopotamab Deruxtecan

AZD5305 + Dato-DXd

Oral PARP inhibitor

IV Antibody-drug conjugate

实验性的:Module 6 AZD5305 + Camizestrant

AZD5305 + Camizestrant

Oral PARP inhibitor

Oral SERD Molecule

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The number of subjects with adverse events/serious adverse events
大体时间:From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.

Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline

From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.
大体时间:From first dose of study treatment until the end of Cycle 1.

A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation. DLTs occurring outside the DLT window (ie, late onset toxicities) may be defined as a DLT after consultation with the sponsor and investigators, based on the emerging safety profile.

From first dose of study treatment until the end of Cycle 1.

次要结果测量

结果测量
措施说明
大体时间
Best percentage change in target lesion
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Change in target lesion size from baseline, as defined by RECIST 1.1.

From Screening to confirmed progressive disease (approximately 1 year)
Objective Response Rate
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Best response until progression, as defined by RECIST 1.1.

From Screening to confirmed progressive disease (approximately 1 year)
Duration of Response
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Time from first response to progression or death , as defined by RECIST 1.1.

From Screening to confirmed progressive disease (approximately 1 year)
Progression Free Survival
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Time from C1D1 to progression or death, as defined by RECIST 1.1.

From Screening to confirmed progressive disease (approximately 1 year)
Time To Response
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Time from C1D1 to complete or partial response, as defined by RECIST 1.1.

From Screening to confirmed progressive disease (approximately 1 year)
Effects of AZD5305 on pH2AX (Ser139) PD biomarker
大体时间:From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)

Measure change from baseline in pH2AX

From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)
CA125 response (ovarian cancer)
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

at least a 50% reduction in CA125 levels from a pre-treatment sample as defined by GCIG criteria.

From Screening to confirmed progressive disease (approximately 1 year)
Module 1: Area Under Curve (AUC)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 1: Maximum plasma concentration of the drug (Cmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 1: The time taken to reach the maximum concentration (Tmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 1 and Module 5: Objective Response Rate (prostate cancer)
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Best response until progression, as defined by RECIST 1.1 or PCWG3 (bone)

From Screening to confirmed progressive disease (approximately 1 year)
Module 1: Radiographic progression free survival (prostate cancer)
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

Time from C1D1 to progression or death, as defined by RECIST 1.1 and PCWG3(bone).

From Screening to confirmed progressive disease (approximately 1 year)
Module 1: Proportion of subjects with ≥ 50% PSA decrease (prostate cancer)
大体时间:From Screening to confirmed progressive disease (approximately 1 year)

PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment

From Screening to confirmed progressive disease (approximately 1 year)
Module 1 : To investigate the effect of a high-fat meal on the PK of AZD5305
大体时间:Cycle 0, Day 1 (C0D1), in either the "fasted" or "fed" state, followed by a single oral dose of AZD5305 in the other state for Cycle 1, Day 1 (C1D1) at least 72 hours later; 1 cycle is 28 days.

Effect on High fat meal on PK parameters of AZD5305.PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without food

Cycle 0, Day 1 (C0D1), in either the "fasted" or "fed" state, followed by a single oral dose of AZD5305 in the other state for Cycle 1, Day 1 (C1D1) at least 72 hours later; 1 cycle is 28 days.
Module 2: Area Under Curve (AUC)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2: Maximum plasma concentration of the drug (Cmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2: The time taken to reach the maximum concentration (Tmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 3: Area Under Curve (AUC)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 3: Maximum plasma concentration of the drug (Cmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 3: The time taken to reach the maximum concentration (Tmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4 : Area Under Curve
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4: Maximum plasma concentration of the drug (Cmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4: The time taken to reach the maximum concentration (Tmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4: Anti-Drug Antibody (ADA)
大体时间:Samples will be collected within 1 hour before dose administration on Day 1 of Cycle 1, 2, and 4, then every 4 Cycles (each cycle is 21 days), EoT, and at safety follow-up (40 days after last dose) as per Schedule of Assessments

To investigate the presence of ADAs for T-DXd

Samples will be collected within 1 hour before dose administration on Day 1 of Cycle 1, 2, and 4, then every 4 Cycles (each cycle is 21 days), EoT, and at safety follow-up (40 days after last dose) as per Schedule of Assessments
Module 4: To assess the preliminary anti-tumour activity of AZD5305 as monotherapy and in combination with T-DXd.
大体时间:From screening to approximately 6 months

Time from C1D1 to progression or death, as defined by RECIST v 1.1 summarised at the 6 month landmark (PFS6)

From screening to approximately 6 months
Module 5: Area Under Curve
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 5: Maximum plasma concentration of the drug (Cmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 5: The time taken to reach the maximum concentration (Tmax)
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 5: Anti-Drug Antibody (ADA)
大体时间:Whole blood samples for determination of ADA for Dato-DXd in plasma will be collected in patients receiving Dato-DXd per the schedule specified in the SoA : Day 1 of Cycle 1, 2, 4, and 8 (each cycle is 21 days) , EoT, and then 28 day follow up visit.

Presence of ADAs for Dato-DXd

Whole blood samples for determination of ADA for Dato-DXd in plasma will be collected in patients receiving Dato-DXd per the schedule specified in the SoA : Day 1 of Cycle 1, 2, 4, and 8 (each cycle is 21 days) , EoT, and then 28 day follow up visit.
Module 5: Premilinary anti tumour activity AZD5305 in combination with Dato-DXd
大体时间:From screening to confirmed progresive disease ( approximately 12 weeks)

objective response rate and radiographic progression-free survival using RECIST v1.1.

Proportion of patients achieving a ≥ 50% decrease in PSA from baseline to the post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response).

From screening to confirmed progresive disease ( approximately 12 weeks)
Module 6: To characterise the PK of AZD5305 and camizestrant following a single dose and at steady state after multiple dosing, when given in combination.
大体时间:At predefined interval throughout the treatment (approximately 12 weeks)

Plasma concentrations and PK parameters of AZD5305 and camizestrant after single dose and multiple dose administration, including, but not limited to:

AUC, Cmax, Tmax, as data allow

At predefined interval throughout the treatment (approximately 12 weeks)
Module 6: To evaluate the effect of camizestrant on the PK of AZD5305.
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without camizestrant.

At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.
大体时间:At predefined intervals throughout the treatment period (approximately 12 weeks)

PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without AZD5305.

At predefined intervals throughout the treatment period (approximately 12 weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Timothy Yap、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年11月12日

初级完成 (估计的)

2027年5月28日

研究完成 (估计的)

2027年5月28日

研究注册日期

首次提交

2020年10月26日

首先提交符合 QC 标准的

2020年11月19日

首次发布 (实际的)

2020年11月25日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅